Sustained Organic Growth in High-Margin Pharmaceutical Business

Dermapharm Holding SE has announced unaudited preliminary figures for the first half of 2024. Despite the end of the pandemic phase in vaccine cooperation, the company saw strong organic growth in its branded pharmaceutical business, which compensated for other segments' performance. Consolidated revenue fell slightly by 0.6% to EUR 578.5 million, while adjusted EBITDA dropped to EUR 153.0 million, down from EUR 168.0 million the previous year. The adjusted EBITDA margin stood at 26.4%.

Management confirmed its full-year forecast, expecting revenues between EUR 1,170–1,210 million and adjusted EBITDA of EUR 305–315 million. The branded pharmaceuticals segment showed robust growth, driven by the rapid reorganization of the Montavit subsidiary and increased expansion in international markets. However, revenue and earnings in the "Other healthcare products" segment declined due to consumer reticence in France.

Dermapharm's performance was in line with projections, supported by product development and acquisitions aimed at external growth. Final audited figures for the first half of 2024 will be published on August 27, 2024.